Tags

Type your tag names separated by a space and hit enter

Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
Eur J Pharmacol. 2010 Jun 25; 636(1-3):28-35.EJ

Abstract

Osteoclasts are specialized bone-resorbing cells derived from multipotent myeloid progenitor cells. They play a crucial homeostatic role in skeletal modeling and remodeling and destroy bone in many pathologic conditions. Receptor activator of NF-kappaB ligand (RANKL) is essential to osteoclastogenesis. In this study, we investigated the effects of Ikarisoside A, isolated from Epimedium koreanum (Berberidaceae), on osteoclastogenesis in RANKL-treated murine monocyte/macrophage RAW 264.7 cells. The results indicate that Ikarisoside A is a potent inhibitor of osteoclastogenesis in RANKL-stimulated RAW 264.7 cells as well as in bone marrow-derived macrophages. The inhibitory effect of Ikarisoside A resulted in decrease of osteoclast-specific genes like matrix metalloproteinase 9 (MMP9), tartrate-resistant acid phosphatase (TRAP), receptor activator of NF-kappaB (RANK), and cathepsin K. Moreover, Ikarisoside A blocked the resorbing capacity of RAW 264.7 cells on calcium phosphate-coated plates. Ikarisoside A also has inhibitory effects on the RANKL-mediated activation of NF-kappaB, JNK, and Akt. Finally, Ikarisoside A clearly decreased the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1) as well as the transcriptional activity of NFATc1, the master regulator of osteoclast differentiation. The data indicate that Ikarisoside A has potential for use in treatment of diseases involving abnormal bone lysis such as osteoporosis, rheumatoid arthritis, and periodontal bone erosion.

Authors+Show Affiliations

Department of Dental Pharmacology, School of Dentistry and Institute of Oral Bioscience, Brain Korea 21 project, Chonbuk National University, Jeon-Ju 561-756, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20353769

Citation

Choi, Hwa Jung, et al. "Inhibition of Osteoclastogenic Differentiation By Ikarisoside a in RAW 264.7 Cells Via JNK and NF-kappaB Signaling Pathways." European Journal of Pharmacology, vol. 636, no. 1-3, 2010, pp. 28-35.
Choi HJ, Park YR, Nepal M, et al. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. Eur J Pharmacol. 2010;636(1-3):28-35.
Choi, H. J., Park, Y. R., Nepal, M., Choi, B. Y., Cho, N. P., Choi, S. H., Heo, S. R., Kim, H. S., Yang, M. S., & Soh, Y. (2010). Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. European Journal of Pharmacology, 636(1-3), 28-35. https://doi.org/10.1016/j.ejphar.2010.03.023
Choi HJ, et al. Inhibition of Osteoclastogenic Differentiation By Ikarisoside a in RAW 264.7 Cells Via JNK and NF-kappaB Signaling Pathways. Eur J Pharmacol. 2010 Jun 25;636(1-3):28-35. PubMed PMID: 20353769.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. AU - Choi,Hwa Jung, AU - Park,Young Ran, AU - Nepal,Manoj, AU - Choi,Bo-Yun, AU - Cho,Nam-Pyo, AU - Choi,Seoung Hwan, AU - Heo,Soo Rye, AU - Kim,Hyung Sup, AU - Yang,Moon-Sik, AU - Soh,Yunjo, Y1 - 2010/03/29/ PY - 2009/07/04/received PY - 2010/02/22/revised PY - 2010/03/14/accepted PY - 2010/4/1/entrez PY - 2010/4/1/pubmed PY - 2010/8/10/medline SP - 28 EP - 35 JF - European journal of pharmacology JO - Eur J Pharmacol VL - 636 IS - 1-3 N2 - Osteoclasts are specialized bone-resorbing cells derived from multipotent myeloid progenitor cells. They play a crucial homeostatic role in skeletal modeling and remodeling and destroy bone in many pathologic conditions. Receptor activator of NF-kappaB ligand (RANKL) is essential to osteoclastogenesis. In this study, we investigated the effects of Ikarisoside A, isolated from Epimedium koreanum (Berberidaceae), on osteoclastogenesis in RANKL-treated murine monocyte/macrophage RAW 264.7 cells. The results indicate that Ikarisoside A is a potent inhibitor of osteoclastogenesis in RANKL-stimulated RAW 264.7 cells as well as in bone marrow-derived macrophages. The inhibitory effect of Ikarisoside A resulted in decrease of osteoclast-specific genes like matrix metalloproteinase 9 (MMP9), tartrate-resistant acid phosphatase (TRAP), receptor activator of NF-kappaB (RANK), and cathepsin K. Moreover, Ikarisoside A blocked the resorbing capacity of RAW 264.7 cells on calcium phosphate-coated plates. Ikarisoside A also has inhibitory effects on the RANKL-mediated activation of NF-kappaB, JNK, and Akt. Finally, Ikarisoside A clearly decreased the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1) as well as the transcriptional activity of NFATc1, the master regulator of osteoclast differentiation. The data indicate that Ikarisoside A has potential for use in treatment of diseases involving abnormal bone lysis such as osteoporosis, rheumatoid arthritis, and periodontal bone erosion. SN - 1879-0712 UR - https://www.unboundmedicine.com/medline/citation/20353769/Inhibition_of_osteoclastogenic_differentiation_by_Ikarisoside_A_in_RAW_264_7_cells_via_JNK_and_NF_kappaB_signaling_pathways_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0014-2999(10)00219-0 DB - PRIME DP - Unbound Medicine ER -